TheraPPI Bioscience
French tech company | Builders Republic
About
Preclinical biotech targeting the ERK/MyD88 protein interaction inside the Ras-MAPK pathway — rather than blocking the pathway as existing inhibitors do, it dysregulates it to kill cancer cells while bypassing the resistance mechanisms that limit current therapies.
Key facts
- Status
- Active
- Sectors
- Healthcare & Life Sciences
- Latest stage
- Pre-seed
- Founded
- 2023
- City
- LYON
- Region
- Auvergne-Rhône-Alpes
- Tracked rounds
- 1
Funding rounds
- Pre-seed · 2026
Investors
- FONGIT
- Satt Pulsalys